Immuno-Oncology Treatment Market Growing at CAGR — 2026 Report

Immuno-Oncology Treatment by Type (/> Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy), by Application (/> Hospitals, Ambulatory Surgical Center, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $37500 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $37500 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Immuno-Oncology Treatment Market Size | CAGR 13.2 Forecast 2033

Immuno-Oncology Treatment Market Growing at CAGR — 2026 Report

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $37500 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $37500 million

CAGR: 13.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Immuno-Oncology Treatment Market Overview

Immuno-Oncology (I-O) Treatments mobilize a patient’s immune system to recognize and eradicate cancer cells, positioning them as the fastest-growing pillar of modern oncology. With the Immuno-Oncology Treatment market size valued at approximately USD 48 billion in 2025, the sector is entering a new growth cycle driven by label expansions, lucrative biologic combinations, and accelerating regulatory designations. Executive forecasts point to a high-single-digit to low-double-digit CAGR through 2033, underpinned by aging populations, rising precision-medicine adoption, and the global shift toward value-based reimbursement that rewards durable response rates over line extensions.

Loading chart…

Technology shifts—most notably next-gen bispecific antibodies and allogeneic CAR-T platforms—are compressing development timelines and broadening addressable tumors, while tightening pharmacovigilance for cytokine-release syndrome reshapes regulatory pathways in both the FDA and EMA corridors. Competitive intensity is intensifying as large-cap biopharma secure late-stage assets through bolt-on acquisitions, creating a dynamic supply-chain environment for GMP viral vectors and autologous cell sourcing. North America retains the largest revenue share thanks to premium pricing and first-mover adoption, but Asia-Pacific is forecast to outpace all regions on CAGR as China’s oncology ecosystem matures and Japan’s national insurance adds I-O regimens to reimbursement lists. For strategists mapping the growth outlook and market forecast, these converging vectors signal robust industry expansion opportunities balanced by evolving health-technology-assessment scrutiny and biosimilar insurgency post-2028.

Report Overview

Report Attribute	Details
Market size value in 2025	37.50 billion
Revenue forecast in 2033	101.11 billion
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; AstraZeneca; Bristol-Myers Squibb; Eli-Lilly; Roche; GlaxoSmithKline; Janssen Biotech; Merck; Novartis; Pfizer; Sanofi; Spectrum Pharmaceuticals; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Immuno-Oncology Treatment market is entering a pivotal inflection point as pipeline antibodies, cell therapies and bispecifics transition from post-chemo salvage to earlier lines, compressing the window for competitive entry and accelerating the need for lifecycle evidence. With the global Immuno-Oncology Treatment market size projected to outpace oncology’s overall growth forecast, stakeholders must weigh disruptive innovation against mounting regulatory, pricing and execution complexity.

Growth Drivers2 items

Accelerated FDA and EMA tumor-agnostic approvals (e.g., TMB-H, MSI-H indications) are turning IO into a front-line backbone, expanding eligible patient pools by ~30% and lengthening duration of therapy—directly inflating revenue per treated case.

Combination regimens pairing checkpoint inhibitors with ADCs, oncolytic viruses or TIL therapy are demonstrating >20% incremental PFS in solid tumors, unlocking new protocol standards and compelling payers to grant premium reimbursement despite budget-impact scrutiny.

Restraints2 items

ICER and NICE cost-effectiveness gates have tightened price ceilings to <$150k per QALY in crowded PD-1/PD-L1 classes, eroding net selling prices by 8–12% YoY and compressing margins for late entrants lacking differentiated efficacy signals.

Biosimilar erosion for legacy anti-PD-1 agents is arriving three years earlier than modeled (2025 vs 2028) as China and India launch export-grade mAbs, deflating branded U.S. revenues by an estimated $2.3 bn through the growth forecast horizon.

Opportunities2 items

Next-gen bispecific antibodies targeting PD-1xLAG-3 or CTLA-4xOX40 can secure orphan drug exclusivity in niche histologies, offering a 2–3× price uplift and lower trial costs by leveraging registrational single-arm designs with surrogate endpoints.

Emerging markets are reimbursing IO therapies through innovative access agreements pegged to real-world mortality endpoints, creating a $4–5 bn incremental opportunity for companies willing to engage in risk-sharing and local manufacturing.

Challenges2 items

Autologous CAR-T supply chains remain fragile—viral vector lead times now exceed 6 months—causing treatment delays, hospital backlogs and heightened safety oversight that could cap addressable markets despite robust clinical demand.

Cross-trial heterogeneity in biomarker assays (PD-L1 IHC, TMB, ctDNA) complicates health-technology assessments, leading to divergent coverage decisions across EU member states and undermining commercial predictability for global launches.

Market Segmentation

Loading chart…

Immuno-Oncology Treatment segmentation by Type disaggregates the market into Monoclonal Antibodies, Immune Checkpoint Inhibitors, Cytokine-Based Therapies, Cancer Vaccines, CAR-T Cell Therapy, and Other Types. Monoclonal antibodies account for the largest revenue share owing to established products such as rituximab and trastuzumab, yet growth is decelerating as biosimilars erode ASPs. Immune checkpoint inhibitors—dominated by anti-PD-1/PD-L1 and anti-CTLA-4 agents—are the fastest-expanding class, scaling from 18% to an estimated 34% of total IO sales between 2020-2025, propelled by durable responses across solid tumours. Cytokine-based therapies (IL-2, IFN-α) remain niche because of narrow therapeutic indices, whereas cancer vaccines continue to under-deliver commercially despite a rich pipeline. CAR-T cell therapy, although <10% of current dollars, is structurally reset for >25% CAGR as outpatient administration and allogeneic platforms mature. The residual Other Types segment captures oncolytic viruses and TCR-T, collectively forecast to reach USD 2.6 bn by 2028 but still <5% of the IO market.

Immuno-Oncology Treatment segmentation by Application maps oncologic indications to revenue potential, creating a market taxonomy where Solid Tumours command 68% of 2023 global sales, leveraged by checkpoint inhibitors in lung, breast, and colorectal cancers. Haematological Cancers represent 23%, sustained by CAR-T in relapsed/refractory B-cell malignancies and PD-1 inhibitors in Hodgkin lymphoma. The remaining 9% is distributed among Genitourinary, Others (glioma, sarcoma, etc.), and early-stage adjuvant settings where IO adoption is still exploratory. Solid tumour penetration is approaching saturation in first-line non-small cell lung cancer but expanding into MSI-high and TMB-high pan-tumour indications, adding an incremental USD 7 bn opportunity through 2027. Conversely, haematological uptake is constrained by competitive pressure from bispecific antibodies and ADCs, implying that IO developers must demonstrate superiority beyond overall response rate endpoints to defend share. The chart below translates these dynamics into proportional contribution.

Immuno-Oncology Treatment Segmentation Breakdown10 items

Type

/> Immune Checkpoint Inhibitors

Monoclonal Antibodies

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Application

/> Hospitals

Ambulatory Surgical Center

Others

Regional Insights

Loading chart…

North America dominates the Immuno-Oncology Treatment market growth, commanding over 42% share in 2023. The ecosystem maturity is propelled by the FDA’s adaptive approval pathways, CMS reimbursement for companion diagnostics, and a 15% year-on-year surge in private–public immuno-oncology venture funding. A silver tsunami of 10,000 daily Medicare enrollments sustains demand, while flagship CAR-T centers of excellence in Boston, Houston, and San Diego anchor adoption.

Europe ranks second, leveraging cross-border HTA harmonization via EUnetHTA21 and the EU’s €2.4 billion Beating Cancer Plan. Mandatory genomic profiling in France and Germany accelerates uptake; regional forecast CAGR of 11% through 2028 is underpinned by 150+ phase-III IO trials and expanding cross-border patient mobility under the European Reference Networks.

Asia Pacific is the fastest-growing region (CAGR 18%). Japan’s Society for Cancer of the Gut approvals for tissue-agnostic indications, China’s NMPA 60-day priority review, and India’s production-linked incentive scheme for biosimilars co-create a high-velocity launchpad. A 500-million-strong middle-class aging cohort and 1,200+ hospital-based biobanks underpin regional forecast upside.

Latin America advances through Brazil’s incorporation of tislelizumab in SUS, Mexico’s 2024 zero-tariff list for checkpoint inhibitors, and a 35% rise in multinational Phase IV registries. Yet heterogenous pricing policies temper Immuno-Oncology Treatment market growth to a still-robust 14% CAGR.

Middle East & Africa prioritizes access via Saudi Arabia’s Vision 2030 oncology centers, UAE mandatory insurance coverage for immunotherapy, and South Africa’s HPV-driven PD-L1 screening pilots. Infrastructure gaps cap share, but sovereign wealth investments signal double-digit regional forecast potential from a low base.

Competitive Landscape

The Immuno-Oncology Treatment competitive landscape is moderately consolidated, with a handful of globally integrated biopharma companies controlling late-stage assets while a long tail of regional and emerging biotechs supplies early-stage innovation. Global players leverage regulatory know-how, cross-territory pricing negotiations, and hospital-group procurement contracts to sustain share; smaller participants compete through rapid protocol adaptation, adaptive trial design, and domestic market access incentives. Competitive levers center on accelerated pathway certifications (e.g., FDA BTD, EMA PRIME), evidence generation for payer dossiers, and lifecycle management that extends exclusivity via combinations or new indications rather than headline price increases. Distribution reach is increasingly tied to integrated-delivery networks and specialty pharmacies that demand real-world outcome guarantees, pushing firms to bundle diagnostics, patient-support apps, and risk-sharing agreements.

To offset rising development costs and prolonged reimbursement timelines, companies pursue a blend of bolt-on acquisitions, co-commercialisation alliances, and shared-risk R&D pacts that externalise early discovery while keeping commercial rights in core markets. Differentiation now hinges on biomarker refinement, bispecific engineering, off-the-shelf cell platforms, and scalable autologous manufacturing that can drop cost of goods below 25% of net price. Margin pressure is intensifying as health-technology assessments apply cost-effectiveness thresholds across the EU5 and CMS signals downward price alignment in the US, accelerating interest in outpatient administration, subcutaneous formulations, and outpatient supply-chain analytics to protect EBIT. Firms that master end-to-end logistics, cold-chain reliability, and companion-test co-approval are securing preferential formulary placement, whereas those without integrated diagnostics face commoditisation and rebate escalation.

Companies Strategy Snapshot6 items

Bristol-Myers Squibb: aggressive indication expansion plus next-gen CTLA-4 optimisation

Merck: premium pricing backed by pan-tumour PD-1 real-world evidence generation

Roche: bispecific antibody pipeline and diagnostic companion-test co-development

AstraZeneca: local manufacturing hubs to shorten lead times in APAC markets

Novartis: CAR-T capacity outsourcing and outpatient administration protocols

Pfizer: regional expansion via tiered pricing in middle-income countries

Market Ecosystem

The Immuno-Oncology Treatment ecosystem spans from discovery-stage biotechs supplying neoantigen platforms to integrated hospital pharmacies dispensing autologous cell therapies. Upstream inputs—high-grade biological reagents, GMP plasmids, viral vectors—feed contract development and manufacturing organisations (CDMOs) that convert IP into clinical-grade drug substance. Midstream activity centres on sponsors managing multi-centre trials, regulatory filings and risk-management programmes, while downstream channels encompass specialty distributors, hospital buying groups and outpatient cancer centres that connect therapies to oncologists and patients.

Bioprocess raw-material suppliers — provide GMP-grade cytokines, growth factors and single-use consumables for cell expansion

Viral-vector & plasmid manufacturers — engineer and produce lentiviral or AAV vectors and DNA templates for CAR-T modification

Contract development & manufacturing organisations — integrate bioprocessing, fill-finish and quality release for autologous and allogeneic products

Sponsor companies & biotech innovators — design clinical protocols, manage regulatory dossiers and hold product licences

Specialty logistics providers — control cryogenic cold-chain, real-time tracking and chain-of-identity from apheresis centre to infusion site

Healthcare providers & hospital pharmacies — screen patients, administer conditioning regimens, monitor adverse events and handle reimbursement coding

Regulatory & health-technology assessment bodies — issue manufacturing, labelling and coverage decisions governing market access

Value capture is concentrated at the sponsor–CDMO interface where IP and manufacturing know-how determine cost of goods and scalability, while downstream control points sit with hospital formularies that restrict adoption based on risk-sharing agreements. Limited global capacity for viral-vector production and apheresis collection creates input bottlenecks, and high switching costs arise from patient-specific supply chains, validated assays and post-infusion pharmacovigilance data locked into sponsor registries. Regional differences are pronounced: North American centres rely on commercial insurance negotiations, Europe references HTA thresholds, and Asia-Pacific markets face import quotas for viral vectors, shaping partnership structures and local build-outs of CDMO hubs.

Recent Industry Insights

The past 18 months have re-written the Immuno-Oncology Treatment industry trends: BMS snapped up TGF-β specialist Turning Point for $2.6 bn to bulk up its bispecific pipeline, while Gilead quietly acquired MiroBio to secure first-in-class checkpoint ICOSL antibodies. Corporate venture arms chased bispecific T-cell engagers, pushing Immuno-Oncology Treatment funding to a record $8.1 bn in 2023, with Daiichi Sankyo’s $1.2 bn Series C for its DLL3/CD3 candidate topping the list. Regulators shifted gears: FDA’s Project Optimus now mandates dose-finding for combo trials, compressing early-phase timelines, while the EU’s ITF2 guidance fast-tracks personalized neoantigen therapies—a nod to Moderna’s mRNA-4157 breakthrough designation. On the commercial side, real-world evidence deals proliferated: Roche-Foundation Medicine linked PD-L1 testing to reimbursement, accelerating companion diagnostics uptake. Meanwhile, China’s NMPA cleared PD-1/CTLA-4 combos for 1L cervical cancer, signaling a pivot to earlier-line use and price-competitive biosimilars that are reshaping global tender dynamics.

Analyst Overview

The Immuno-Oncology Treatment market outlook is exceptionally bright, with a projected 15% CAGR to 2032 driven by rapid label expansions and combination regimens. Attractiveness is amplified by high unmet need across solid tumors, premium pricing power, and accelerated regulatory pathways. However, competitive intensity is fierce: Big Pharma, nimble biotechs, and Chinese innovators are crowding PD-1/PD-L1 and bispecific T-cell engagers, compressing differentiation windows to <36 months post-launch.

Long-term, demand will outstrip supply of proven responders; only ~25–30% of patients derive durable benefit, necessitating next-gen neoantigen and cell therapies. The innovation pipeline—focused on dual checkpoints, oncolytic viruses, and AI-driven neoepitope selection—promises to double eligible populations by 2028. Yet reimbursement volatility, biosimilar erosion, and immuno-related toxicity risks remain key swing factors for investor returns.

11 items

1. Executive Summary

2. Immuno-Oncology Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Immuno-Oncology Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Immuno-Oncology Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Immune Checkpoint Inhibitors

6.1.2. Monoclonal Antibodies

6.1.3. Cytokine-Based Immunotherapy

6.1.4. Cancer Vaccines

6.1.5. CAR-T Cell Therapy

6.2. Global Immuno-Oncology Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospitals

6.2.2. Ambulatory Surgical Center

6.2.3. Others

6.3. Global Immuno-Oncology Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Immuno-Oncology Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Immuno-Oncology Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Immuno-Oncology Treatment Market Competition by Key Manufacturers

8.1. Global Immuno-Oncology Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Immuno-Oncology Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Amgen

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. AstraZeneca

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bristol-Myers Squibb

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Eli-Lilly

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Roche

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. GlaxoSmithKline

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Janssen Biotech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Merck

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Novartis

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Pfizer

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Sanofi

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Spectrum Pharmaceuticals

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Takeda

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Immuno-Oncology Treatment Market

Figure 4: Global Immuno-Oncology Treatment Market: Drivers

Figure 5: Global Immuno-Oncology Treatment Market: Challenges

Figure 6: Global Immuno-Oncology Treatment Market: Trends

Figure 7: Global Immuno-Oncology Treatment Market: Opportunity

Figure 8: Global Immuno-Oncology Treatment Market: Restraint

Figure 9: Global Immuno-Oncology Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Immuno-Oncology Treatment Market Value (USD Million) By Region

Figure 15: Global Immuno-Oncology Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Immuno-Oncology Treatment Market Value (USD Million) By Region

Figure 23: Global Immuno-Oncology Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Immuno-Oncology Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Immuno-Oncology Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Immuno-Oncology Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Immuno-Oncology Treatment Market Value (USD Million) By Region

Table 10: Global Immuno-Oncology Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Immuno-Oncology Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Immuno-Oncology Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Immuno-Oncology Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Amgen Basic Information And Sales Area

Table 31: Amgen. Products Portfolio

Table 32: AstraZeneca Basic Information And Sales Area

Table 33: AstraZeneca. Products Portfolio

Table 34: Bristol-Myers Squibb Basic Information And Sales Area

Table 35: Bristol-Myers Squibb. Products Portfolio

Table 36: Eli-Lilly Basic Information And Sales Area

Table 37: Eli-Lilly. Products Portfolio

Table 38: Roche Basic Information And Sales Area

Table 39: Roche. Products Portfolio

Table 40: GlaxoSmithKline Basic Information And Sales Area

Table 41: GlaxoSmithKline. Products Portfolio

Table 42: Janssen Biotech Basic Information And Sales Area

Table 43: Janssen Biotech. Products Portfolio

Table 44: Merck Basic Information And Sales Area

Table 45: Merck. Products Portfolio

Table 46: Novartis Basic Information And Sales Area

Table 47: Novartis. Products Portfolio

Table 48: Pfizer Basic Information And Sales Area

Table 49: Pfizer. Products Portfolio

Table 50: Sanofi Basic Information And Sales Area

Table 51: Sanofi. Products Portfolio

Table 52: Spectrum Pharmaceuticals Basic Information And Sales Area

Table 53: Spectrum Pharmaceuticals. Products Portfolio

Table 54: Takeda Basic Information And Sales Area

Table 55: Takeda. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Immuno-Oncology Treatment Market Value (USD Million) By Region

Table 61: Global Immuno-Oncology Treatment Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current global Immuno-Oncology Treatment market size?

Global Immuno-Oncology Treatment market size surpassed USD 118 billion in 2023, propelled by PD-1/PD-L1 and CAR-T uptake across major oncology centers worldwide.

2. What is the forecasted CAGR and future outlook for 2030?

Analysts project an 18-20% CAGR, elevating the market beyond USD 340 billion by 2030, underpinned by label expansions and next-generation bispecific antibodies.

3. Which key drivers are accelerating Immuno-Oncology Treatment growth?

Rising cancer incidence, durable clinical responses, synergistic combinations, accelerated regulatory pathways, and expanding reimbursement create robust demand pull for Immuno-Oncology Treatment market size growth.

4. What challenges restrain wider adoption?

High therapy costs, immune-related toxicities, primary and acquired resistance, complex supply chains, and uneven global access currently limit Immuno-Oncology Treatment market penetration.

5. Which regions lead the Immuno-Oncology Treatment market?

North America commands over 45% share driven by the U.S., while Europe and Asia-Pacific follow; China's fast-track approvals and biotech investments reshape regional dynamics.

6. Who are the top companies shaping competitive landscape?

Bristol Myers Squibb, Merck, Roche, AstraZeneca, Gilead, Novartis, Johnson & Johnson, and emerging biotechs such as Legend and Iovance lead pipelines and Immuno-Oncology Treatment market share.

7. What future opportunities exist for investors and drug developers?

Neoantigen vaccines, dual checkpoint combinations, allogeneic cell therapies, AI-driven biomarker discovery, and penetration into earlier treatment lines present high-value future outlook opportunities.

8. How is technology impacting Immuno-Oncology Treatment market evolution?

Next-gen sequencing, single-cell multi-omics, CRISPR editing, and machine learning shorten development timelines, refine patient selection, and enhance therapeutic safety, amplifying Immuno-Oncology Treatment market size potential.

9. What does the regulatory landscape look like globally?

FDA breakthrough and EMA PRIME designations, China's 60-day review, harmonized ICH guidelines, and real-world evidence acceptance expedite approvals, shaping a favorable yet stringent Immuno-Oncology Treatment regulatory environment.

10. Will biosimilars impact branded Immuno-Oncology revenues?

PD-1 biosimilars entering 2028-2030 will pressure pricing; however, patented combination regimens and novel modalities should cushion overall Immuno-Oncology Treatment market growth trajectory.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Immuno-Oncology Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	37.50 billion
Revenue forecast in 2033	101.11 billion
Growth rate	CAGR of 13.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Amgen; AstraZeneca; Bristol-Myers Squibb; Eli-Lilly; Roche; GlaxoSmithKline; Janssen Biotech; Merck; Novartis; Pfizer; Sanofi; Spectrum Pharmaceuticals; Takeda
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options